U.S. Patents & Applications
PantarhinTMdevelops enzyme–based therapies and platform technologies for targeted modulation of the extracellular matrix. The focus is on innovative enzyme designs that influence pathological ECM structures in cardiovascular diseases, with the aim of creating new therapeutic options for serious genetic metabolic disorders and vascular diseases.
What makes us special:
Dualactionlike enzyme design (D016):
A hybrid enzyme concept that specifically targets HA and relevant chondroitin sulfate structures and thus influences ECMRemodeling. Scientific foundation: Previous preclinical validation by specialized partners; solid IP strategy protects our approaches.
Scalability:
From recombinant production to clinical development – with robust manufacturing and supply chain solutions.
Regulatory path:
Clear roadmap from preclinical to clinical phases to potential approval, supported by an experienced regulatory team.
Applications listed below are acitve or under license and/or pending; prosecution status may evolve. No freedom-to-operate or regulatory approval is implied. Jurisdictional scopes may differ.
| Jurisdiction | Type / No. | Title | Status |
|---|---|---|---|
| US | Patent No. 10,086,051 (B2) | Use of hyaluronidase for the prevention or treatment of arterial hypertension or cardiac insufficienc. | Active • Issued 2018-11-21 |
| US | Patent No. 11,000,575 (B2) | Use of hyaluronidase for the prevention or treatment of arterial hypertension or cardiac insufficiency. | Active • Issued 2021-05-11 |
| Application Published – Licensed IP | |||
| US | 2024 0415940 (A1) | Hyaluronidase polypeptide for the treatment or prophylaxis of a neurodegenerative disease and/or a dysfunctional blood-brain barrier. | Pending • Licensee 2024-12-19 |
| US | 2023 0167428 (A1) | A modified bacterial hyaluronidase polypeptide, production process, pharmaceutical compositions and their uses. | Pending • Licensee 2023-03-02 |
Historical application US 20080124316 is expired.